07:35:26 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 Ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma 2019
2019-02-04 Ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Polarcool är verksamma inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2022-10-04 10:16:00

The med-tech company PolarCool AB (publ) continues its establishment in professional rugby, by signing a 2-year agreement with the Gallagher Premiership rugby team London Irish for the use of the PolarCap System.

PolarCool develops the product PolarCap®, which alleviates the effects of concussion. The company's primary customers are sports with an increased risk of concussion, such as Ice Hockey, Rugby, Football and Handball. The agreement with London Irish has a limited financial impact but is another important step in the company's establishment in the rugby market. PolarCool has recently secured several strategic agreements with professional rugby clubs in both France and United Kingdom.

London Irish are a professional Rugby Union team competing in the Gallagher Premiership, the top division of English Rugby Union. The club has a rich history and was founded in 1898 following the creation of London Scottish and London Welsh, historically for the reason of allowing Irishmen the chance to play rugby with fellow countrymen in the English Capital.

Brian O'Leary, Head of Performance at London Irish, comments:

-The treatment and management of concussions is important to us at London Irish. We have reviewed the scientific evidence based on the PolarCap System and we are encouraged to use and evaluate the device and offer improved medical treatment for our players who may suffer a concussion

Erik Andersson, PolarCool's CEO comments:

-In our ongoing establishment on the British market, it is now gratifying that we have received our first agreement within Premiership Rugby. We notice that the wish for solutions regarding the problems with head injuries in the rugby world are large. The fact that the sport has many practitioners and clubs, both in Europe and in the world, makes this market very interesting for PolarCool. With more and more clubs starting to provide PolarCap to their players we envisage an accelerating establishment in this market segment alongside establishing PolarCap® in other sports in the UK.

Rugby is one of PolarCool's most important markets, as the sport has more than 180,000 clubs and 6.6 million players globally. The concussion rate in rugby is high putting rugby players at a larger risk of injury compared to athletes in other sports.